吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GILD 吉利德科学

休市中 07-24 16:00:00 EDT

129.31

-1.55

-1.18%

盘后129.98

+0.67+0.52%

19:53 EDT

最高131.65	最低129.04	成交量552.97万
今开130.93	昨收130.86	日振幅2.00%
总市值1,604亿	流通市值1,601亿	总股本12.41亿
成交额7.18亿	换手率0.45%	流通股本12.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":129.31,"timestamp":1784923200000,"preClose":130.86,"halted":0,"volume":5529739,"hourTrading":{"tag":"盘后","latestPrice":129.98,"preClose":129.31,"latestTime":"19:53 EDT","volume":247671,"amount":32026245.7962,"timestamp":1784937237301,"change":0.67,"changeRate":0.005181,"amplitude":0.008352},"delay":0,"changeRate":-0.011844719547608216,"floatShares":1238162880,"shares":1240679623,"eps":7.352725,"marketStatus":"休市中","change":-1.55,"latestTime":"07-24 16:00:00 EDT","open":130.93,"high":131.6525,"low":129.04,"amount":718067299.20145,"amplitude":0.019964,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.352725,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":696056400000,"exchange":"NASDAQ","adjPreClose":130.86,"dividendRate":0.024669,"preHourTrading":{"tag":"盘前","latestPrice":130.99,"preClose":130.86,"latestTime":"09:29 EDT","volume":1833,"amount":240559.29066,"timestamp":1784899794049,"change":0.13,"changeRate":0.000993,"amplitude":0.017423},"postHourTrading":{"tag":"盘后","latestPrice":129.98,"preClose":129.31,"latestTime":"19:53 EDT","volume":247671,"amount":32026245.7962,"timestamp":1784937237301,"change":0.67,"changeRate":0.005181,"amplitude":0.008352},"volumeRatio":0.9084397976915883,"impliedVol":0.3547,"impliedVolPercentile":0.8088},"requestUrl":"/m/hq/s/GILD","defaultTab":"news","newsList":[{"id":"2653895100","title":"吉利德科学(GILD)肿瘤组合疗法获欧洲药品管理局旗下CHMP推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2653895100","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653895100?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:45","pubTimestamp":1784889935,"startTime":"0","endTime":"0","summary":"金吾财讯 | 吉利德科学 宣布，欧洲药品管理局旗下人用药品委员会已发布积极意见，建议批准其Trop-2靶向ADC药物Trodelvy联合帕博利珠单抗，用于既往未接受过全身治疗、且肿瘤PD-L1表达阳性的不可切除局部晚期或转移性三阴性乳腺癌成人患者。若欧盟委员会于2026年晚些时候正式批准该联合疗法，Trodelvy将实现从单药到联合疗法、全面覆盖不同PD-L1表达状态的mTNBC一线治疗布局。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NmQ4YmNlMWEyMTYyODU5MDQwMjQzMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NmQ4YmNlMWEyMTYyODU5MDQwMjQzMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302998","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","SG9999015945.SGD","LU0965509101.SGD","LU2468319806.SGD","LU1037948541.HKD","LU1571399168.USD","LU1066051498.USD","TBXU","BK4139","BBH","BIB","IBBQ","BK4568","LU0965508806.USD","LU1057294990.SGD","BK4585","LU2324357040.USD","LU0823416689.USD","IE00BZ1G4Q59.USD","TMED","LU1585245621.USD","CHMP","LU1934455863.HKD","LU2087621335.USD","LU0234570918.USD","IE00BSNM7G36.USD","LU0058720904.USD","MEDI","BK4578","SG9999015978.USD","BK4550","LU1023059063.AUD","IE0002270589.USD","LU1934455194.USD","IE00B3T34201.USD","SG9999015952.SGD","BK4588","BMED","IE00B19Z3581.USD","LU1674673428.USD","LU0965509010.AUD","GILD","LU0122379950.USD","LU0889565916.HKD","LU0289739699.SGD","SG9999015986.USD","LU2089984988.USD","BK4583","LU1061106388.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185859812","title":"CHMP推荐吉利德Trodelvy®联合Keytruda®用于PD-(L)1阳性一线转移性三阴性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1185859812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185859812?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:29","pubTimestamp":1784888958,"startTime":"0","endTime":"0","summary":"欧洲药品管理局人用药品委员会（CHMP）近日给出推荐意见，支持吉利德科学的Trodelvy®与Keytruda®联合使用，用于治疗PD-(L)1阳性的一线转移性三阴性乳腺癌患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","GILD","TMED","LU0889565916.HKD","BBH","LU2089984988.USD","BK4588","IE00B19Z3581.USD","IBBQ","LU1066053197.SGD","LU1674673691.USD","LU2468319806.SGD","LU0234570918.USD","BK4583","LU0114720955.EUR","LU0122379950.USD","LU1057294990.SGD","LU0289739699.SGD","LU1066051498.USD","LU1585245621.USD","SG9999015978.USD","BK4550","BK4139","LU1037948897.HKD","LU0882574055.USD","LU0965508806.USD","LU1674673428.USD","LU0109394709.USD","LU0965509101.SGD","LU1061106388.HKD","BK4566","LU0965509010.AUD","IE0002270589.USD","LU1934455863.HKD","SG9999015952.SGD","BIB","LU2087621335.USD","LU0058720904.USD","LU2324357040.USD","BK4532","SG9999015945.SGD","BMED","LU0965509283.SGD","LU1023059063.AUD","IE00BSNM7G36.USD","LU1571399168.USD","LU0861579265.USD","IE00BZ1G4Q59.USD","BK4568","LU2112291526.USD","LU1037948541.HKD","BK4578","SG9999015986.USD","LU1839511570.USD","LU1934455277.USD","MEDI","IBB","LU1934455194.USD","LU0823416689.USD","LU1430594728.SGD","LU1778281490.HKD","IE00B19Z3B42.SGD","LU0320765992.SGD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","TBXU","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169878111","title":"Leerink Partners下调吉利德科学评级至“与大盘持平”，目标价大幅调降至127美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169878111","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169878111?lang=zh_cn&edition=full","pubTime":"2026-07-21 12:03","pubTimestamp":1784606620,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners调整了对生物技术公司吉利德科学的股票评级。该机构将其评级从原先的“跑赢大盘”下调至“与大盘持平”，反映出其对该公司近期前景更为审慎的看法。\n与此同时，Leerink Partners也显著下调了吉利德科学的目标股价，从每股146美元大幅削减至127美元。这一调整意味着该机构对该公司未来股价的预期有所降低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","LU2112291526.USD","LU0823416689.USD","BK4578","GILD","LU0058720904.USD","IE00B3T34201.USD","IBB","BK4583","LU0965509101.SGD","BK4568","TBXU","SG9999015945.SGD","LU1839511570.USD","BK4139","LU1934455863.HKD","LU1023059063.AUD","BIB","IE00BZ1G4Q59.USD","LU1037948897.HKD","IBBQ","LU0320765992.SGD","LU0234570918.USD","LU1934455277.USD","LU2089984988.USD","LU1674673428.USD","IE00B7SZLL34.SGD","BK4585","LU0965509283.SGD","BK4588","LU0109394709.USD","LU0965509010.AUD","BMED","IE00BSNM7G36.USD","LU1430594728.SGD","LU0114720955.EUR","LU0882574055.USD","LU1571399168.USD","TMED","IE00BKVL7J92.USD","LU1037948541.HKD","LU1674673691.USD","LU1061106388.HKD","LU1585245621.USD","MEDI","LU0289739699.SGD","LU0889565916.HKD","LU2468319806.SGD","SG9999015978.USD","LU1066051498.USD","LU2324357040.USD","BK4532","BK4550","LU1066053197.SGD","LU0965508806.USD","BBH","LU2087621335.USD","SG9999015986.USD","BK4566","LU0861579265.USD","LU1057294990.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","SG9999015952.SGD","LU0122379950.USD","IE0002270589.USD","LU1934455194.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653210240","title":"Leerink下调吉利德科学目标价至127美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653210240","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653210240?lang=zh_cn&edition=full","pubTime":"2026-07-21 10:35","pubTimestamp":1784601350,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0882574055.USD","IE00B19Z3B42.SGD","LU0823416689.USD","LU2089984988.USD","IE00B7SZLL34.SGD","MEDI","LU0889565916.HKD","LU0114720955.EUR","LU1778281490.HKD","LU2112291526.USD","LU2324357040.USD","LU1037948541.HKD","LU1066053197.SGD","LU1839511570.USD","BK4139","LU2468319806.SGD","LU2087621335.USD","LU0234570918.USD","LU0965509010.AUD","BMED","IBB","LU1023059063.AUD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0320765992.SGD","LU1674673428.USD","LU1934455863.HKD","SG9999015978.USD","BBH","LU0109394709.USD","LU0289739699.SGD","LU0058720904.USD","BK4585","BK4578","BK4550","GILD","LU0965509101.SGD","UUP","UDN","SG9999015986.USD","LU0965509283.SGD","IBBQ","SG9999015945.SGD","BK4583","BIB","LU1674673691.USD","IE00BKVL7J92.USD","LU0122379950.USD","LU0861579265.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117996754","title":"异动解读｜吉利德科学盘中上涨3.02%，生物科技板块整体走强带动","url":"https://stock-news.laohu8.com/highlight/detail?id=1117996754","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117996754?lang=zh_cn&edition=full","pubTime":"2026-07-17 02:59","pubTimestamp":1784228365,"startTime":"0","endTime":"0","summary":"7月17日，吉利德科学盘中上涨3.02%，报135.685美元/股，成交额4.64亿美元，跟随生物科技板块整体走强。消息面上，同板块大型生物科技股集体上涨，艾伯维涨3.28%、安进涨3.03%、福泰制药涨1.36%，吉利德涨幅与行业龙头基本同步。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127464857","title":"异动解读｜吉利德科学夜盘上涨3.2%，汇丰上调评级至买入提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1127464857","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127464857?lang=zh_cn&edition=full","pubTime":"2026-07-13 12:01","pubTimestamp":1783915294,"startTime":"0","endTime":"0","summary":"7月13日，吉利德科学夜盘上涨3.2%，报133.99美元/股，成交额43.42万美元，从此前连续回调中明显反弹。消息面上，汇丰近日将吉利德科学评级从持有上调至买入，目标价从133美元大幅上调至155美元，为股价提供支撑。此外，公司核心产品Trodelvy于6月底获FDA批准用于晚期三阴性乳腺癌一线治疗，可作为单药或联合默沙东Keytruda使用，NCCN已将其列为1类优选方案，为公司肿瘤板块打开新增长空间。此前股价因生物科技板块整体走弱而回撤，当前反弹或反映市场对基本面利好的重新定价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103227133","title":"异动解读｜吉利德科学盘中下跌3.04%，报130.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103227133","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103227133?lang=zh_cn&edition=full","pubTime":"2026-07-10 23:47","pubTimestamp":1783698441,"startTime":"0","endTime":"0","summary":"7月10日，吉利德科学盘中下跌3.04%，报130.74美元/股，成交额2.42亿美元。吉利德科学所在的生物科技行业中，个股普遍走弱，其中艾伯维公司跌1.34%，Moderna跌10.25%，Ionis Pharmaceuticals跌8.87%，阿尔尼拉姆制药公司跌4.37%，BridgeBio Pharma跌3.41%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186997657","title":"异动解读 | 汇丰上调评级至买入叠加产品利好，吉利德科学盘中大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186997657","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186997657?lang=zh_cn&edition=full","pubTime":"2026-07-08 03:57","pubTimestamp":1783454231,"startTime":"0","endTime":"0","summary":"吉利德科学(GILD)今日盘中大涨5.02%，引起了市场的广泛关注。消息面上，汇丰将吉利德科学的评级从“持有”上调至“买入”，并将其目标价从133美元大幅上调至155美元，这为股价走强提供了直接催化。此外，公司近期基本面利好密集：其抗癌药物Trodelvy先后获得美国FDA及欧盟批准，用于三阴性乳腺癌的一线治疗；在HIV领域，lenacapavir的多项三期试验达到主要终点，且每日一次的复方HIV疗法获得了FDA的优先审评资格。这些进展共同增强了市场对公司未来业绩的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189055916","title":"异动解读｜吉利德科学盘中上涨3.09%，汇丰上调评级至买入","url":"https://stock-news.laohu8.com/highlight/detail?id=1189055916","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189055916?lang=zh_cn&edition=full","pubTime":"2026-07-07 22:07","pubTimestamp":1783433230,"startTime":"0","endTime":"0","summary":"7月7日，吉利德科学盘中上涨3.09%，报134.84美元/股，成交额1.73亿美元。消息面上，汇丰于7月6日将吉利德科学评级从\"持有\"上调至\"买入\"，目标价从133美元大幅上调至155美元，较当前股价有约15%的上行空间。此次评级上调或为今日股价走强的直接催化。FactSet汇总分析师平均目标价为160.74美元，整体评级为\"买入\"。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156535819","title":"异动解读｜吉利德科学盘中上涨3.06%，Trodelvy获FDA批准一线治疗三阴性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1156535819","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156535819?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:27","pubTimestamp":1783002440,"startTime":"0","endTime":"0","summary":"7月2日，吉利德科学盘中上涨3.06%，报129.83美元/股，成交额7444.03万美元。消息面上，FDA近日正式批准Trodelvy用于晚期三阴性乳腺癌一线治疗，可单药用于不适合PD-1抑制剂的患者，也可联合默沙东Keytruda用于PD-L1阳性患者。NCCN同步更新指南，将Trodelvy列为转移性TNBC一线首选治疗方案。此次获批标志着Trodelvy从后线治疗跃升至一线核心用药，大幅拓展其商业化前景，叠加公司HIV长效新药组合获FDA优先审评、Arcellx及Tubulis并购落地，吉利德肿瘤与抗病毒双管线驱动逻辑持续强化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107662586","title":"异动解读｜吉利德科学盘中上涨3.18%，Trodelvy获FDA批准用于三阴性乳腺癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1107662586","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107662586?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:29","pubTimestamp":1782484183,"startTime":"0","endTime":"0","summary":"消息面上，美国FDA正式批准公司核心肿瘤药物Trodelvy用于晚期三阴性乳腺癌成人患者的一线治疗，包括作为单药疗法以及与默沙东Keytruda联合用药方案。美国国家综合癌症网络已更新指南，将Trodelvy列为转移性三阴性乳腺癌的1类首选一线治疗方案。此外，欧盟委员会也于近日批准Trodelvy用于不适合PD-1抑制剂治疗的转移性三阴性乳腺癌患者的一线治疗，全球监管进展顺利，进一步打开Trodelvy在乳腺癌领域的商业化空间。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181778029","title":"FDA批准Sacituzumab Govitecan-hziy作为单药及与Pembrolizumab联合用于三阴性乳腺癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1181778029","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181778029?lang=zh_cn&edition=full","pubTime":"2026-06-25 03:04","pubTimestamp":1782327863,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已批准Sacituzumab Govitecan-hziy作为单药疗法，以及与Pembrolizumab联合用药方案，用于三阴性乳腺癌患者的一线治疗。这一监管决定为这类侵袭性乳腺癌亚型患者提供了新的重要治疗选择。Sacituzumab Govitecan-hziy是一种靶向Trop-2抗原的抗体药物偶联物。此次FDA的批准基于一项关键临床试验的积极数据，该数据显示该疗法在延长患者无进展生存期和总生存期方面展现出潜力。这一批准标志着三阴性乳腺癌治疗领域的一个重要进展，有望改善患者的临床结局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE0002270589.USD","LU0861579265.USD","LU2087621335.USD","LU1430594728.SGD","SG9999015986.USD","LU0965509283.SGD","LU0109394709.USD","LU1934455863.HKD","LU0965509101.SGD","BK4568","LU1066051498.USD","BK4588","BK4139","BK4578","SG9999015945.SGD","LU0122379950.USD","LU0289739699.SGD","BK4566","LU0882574055.USD","LU1057294990.SGD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","SG9999015952.SGD","LU0058720904.USD","BK4550","LU1778281490.HKD","GILD","IE00B3T34201.USD","LU0114720955.EUR","LU1066053197.SGD","LU0965509010.AUD","LU1585245621.USD","LU1934455194.USD","LU2089984988.USD","LU1934455277.USD","LU2468319806.SGD","LU1037948541.HKD","LU1674673691.USD","LU0889565916.HKD","LU1839511570.USD","LU1037948897.HKD","LU0234570918.USD","LU1023059063.AUD","IE00BZ1G4Q59.USD","LU0823416689.USD","LU1061106388.HKD","LU1571399168.USD","LU1674673428.USD","BK4583","LU2112291526.USD","SG9999015978.USD","IE00BKVL7J92.USD","LU2324357040.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4585","BK4532","LU0965508806.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199544866","title":"欧盟委员会批准Trodelvy®作为不适合Pd-(L)1抑制剂的转移性三阴性乳腺癌患者的一线治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1199544866","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199544866?lang=zh_cn&edition=full","pubTime":"2026-06-23 19:45","pubTimestamp":1782215122,"startTime":"0","endTime":"0","summary":"欧盟委员会已正式批准Trodelvy用于治疗不适合接受Pd-1抑制剂治疗的转移性三阴性乳腺癌患者，将其确立为首选的一线疗法。这一监管决定标志着针对这一难治性乳腺癌亚型患者群体的治疗格局取得了重要进展。随着监管批准的落地，医疗专业人士将能够为特定的转移性三阴性乳腺癌患者提供这一靶向Trop-2抗原的抗体药物偶联物作为初始系统性治疗方案，有望改善患者的临床结局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","LU1430594728.SGD","IE00BZ1G4Q59.USD","BK4578","LU1674673428.USD","IE0002270589.USD","LU0289739699.SGD","LU2112291526.USD","SG9999015978.USD","LU1066051498.USD","BK4550","BK4139","BK4532","LU0114720955.EUR","LU0320765992.SGD","LU1057294990.SGD","LU1037948897.HKD","LU0122379950.USD","LU1585245621.USD","LU0965509010.AUD","BK4566","LU2468319806.SGD","SG9999015945.SGD","IE00B7SZLL34.SGD","LU1839511570.USD","LU1037948541.HKD","LU2089984988.USD","LU1778281490.HKD","SG9999015952.SGD","BK4568","LU0965508806.USD","GILD","LU0965509283.SGD","LU0861579265.USD","LU0882574055.USD","LU1066053197.SGD","LU0965509101.SGD","LU1934455194.USD","LU0109394709.USD","LU0889565916.HKD","LU0058720904.USD","BK4583","LU0823416689.USD","LU1571399168.USD","BK4588","LU1674673691.USD","IE00B19Z3B42.SGD","SG9999015986.USD","IE00BSNM7G36.USD","LU1061106388.HKD","LU1934455277.USD","BK4585","LU1934455863.HKD","IE00B19Z3581.USD","IE00B3T34201.USD","LU2324357040.USD","IE00BKVL7J92.USD","LU1023059063.AUD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101683865","title":"异动解读｜吉利德科学盘中上涨3.06%，FDA接受Yeztugo每周一次口服HIV预防药物申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1101683865","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101683865?lang=zh_cn&edition=full","pubTime":"2026-06-16 23:43","pubTimestamp":1781624595,"startTime":"0","endTime":"0","summary":"6月16日，吉利德科学盘中上涨3.06%，报128.1美元/股，成交额2.87亿美元。消息面上，美国FDA已接受吉利德科学提交的Yeztugo300mg片剂的补充新药申请，用于每周一次口服HIV暴露前预防，PDUFA目标日期为明年2月2日。此外，此前公布的Islatravir/Lenacapavir每周一次口服HIV治疗方案两项三期试验均达主要终点，进一步夯实公司HIV管线优势。该股此前因Trodelvy肺癌三期试验终止而持续承压，HIV管线连续利好推动股价修复反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171165703","title":"异动解读｜吉利德科学盘中上涨3.52%，HIV新药积极数据助力股价超跌反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1171165703","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171165703?lang=zh_cn&edition=full","pubTime":"2026-06-11 21:58","pubTimestamp":1781186338,"startTime":"0","endTime":"0","summary":"6月11日，吉利德科学盘中上涨3.52%，报125.095美元/股，成交额1.01亿美元。此前该股因Trodelvy联合Keytruda一线治疗转移性非小细胞肺癌的III期研究被终止而连续承压，累计跌幅显著。消息面上，吉利德科学与默沙东此前公布的HIV药物Islatravir/Lenacapavir口服每周一次治疗方案两项三期试验均达到第48周主要疗效终点，且不劣于必妥维和标准抗逆转录病毒疗法，两家公司计划向全球监管机构提交申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194875002","title":"国家艾滋病纪念园与吉利德基金会启动重大投资，扩展艾滋病教育与社区领导力","url":"https://stock-news.laohu8.com/highlight/detail?id=1194875002","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194875002?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:34","pubTimestamp":1781181267,"startTime":"0","endTime":"0","summary":"国家艾滋病纪念园与吉利德基金会宣布，将启动一项重大投资项目，旨在显著扩展艾滋病相关的教育项目并加强社区的领导能力建设。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BK4588","LU0109394709.USD","LU0114720955.EUR","LU0965509283.SGD","LU1023059063.AUD","LU0289739699.SGD","BK4585","IE00B19Z3581.USD","LU1037948897.HKD","LU1585245621.USD","IE00B3T34201.USD","LU1061106388.HKD","LU1839511570.USD","LU1674673691.USD","BK4566","LU2089984988.USD","LU1066051498.USD","LU0122379950.USD","LU1934455194.USD","LU1778281490.HKD","LU0889565916.HKD","IE00B7SZLL34.SGD","SG9999015978.USD","SG9999015986.USD","LU1037948541.HKD","SG9999015952.SGD","LU1571399168.USD","LU0965509010.AUD","LU2468319806.SGD","BK4532","BK4578","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU1934455277.USD","BK4583","BK4139","LU0320765992.SGD","SG9999015945.SGD","LU1934455863.HKD","IE00B19Z3B42.SGD","LU0965508806.USD","LU0861579265.USD","LU1066053197.SGD","BK4550","LU2087621335.USD","IE00BSNM7G36.USD","LU2324357040.USD","LU1430594728.SGD","GILD","BK4568","LU0058720904.USD","LU0882574055.USD","LU2112291526.USD","IE00BKVL7J92.USD","IE0002270589.USD","LU0823416689.USD","LU1057294990.SGD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167309488","title":"异动解读｜吉利德科学盘中下跌3.06%，Trodelvy肺癌三期试验终止持续施压","url":"https://stock-news.laohu8.com/highlight/detail?id=1167309488","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167309488?lang=zh_cn&edition=full","pubTime":"2026-06-11 01:36","pubTimestamp":1781113006,"startTime":"0","endTime":"0","summary":"6月11日，吉利德科学盘中下跌3.06%，报121.66美元/股，成交额5.19亿美元。消息面上，吉利德科学与默沙东此前宣布，基于数据监测委员会建议，终止Trodelvy联合Keytruda一线治疗转移性非小细胞肺癌的III期KEYNOTE-D46/EVOKE-03研究。Trodelvy作为吉利德肿瘤管线核心资产，该试验失败对其肿瘤业务拓展构成打击。此外，加拿大皇家银行指出体内CAR-T早期技术可能威胁吉利德未来10%至15%的收入，进一步加剧市场担忧。同期公布的HIV药物Islatravir/Lenacapavir三期积极数据未能有效对冲肿瘤管线利空。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119573472","title":"异动解读｜吉利德科学盘中下跌3.29%，Trodelvy联合Keytruda肺癌三期试验宣布终止","url":"https://stock-news.laohu8.com/highlight/detail?id=1119573472","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119573472?lang=zh_cn&edition=full","pubTime":"2026-06-09 22:07","pubTimestamp":1781014061,"startTime":"0","endTime":"0","summary":"6月9日，吉利德科学盘中下跌3.29%，报123.73美元/股，成交额1.6亿美元。消息面上，吉利德科学与默沙东宣布，基于数据监测委员会的建议，终止Trodelvy联合Keytruda一线治疗转移性非小细胞肺癌的III期KEYNOTE-D46/EVOKE-03研究。Trodelvy是吉利德肿瘤管线核心资产，该试验失败对其肿瘤业务拓展构成打击。同日公布的HIV药物Islatravir/Lenacapavir三期积极数据未能对冲肿瘤管线利空。吉利德科学公司是一家以研究为基础的生物制药公司，主要聚焦病毒性疾病、炎性和纤维化疾病以及肿瘤学领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642545787","title":"默沙东(MRK.US)与吉利德科学(GILD.US)联合HIV药物三期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2642545787","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642545787?lang=zh_cn&edition=full","pubTime":"2026-06-09 14:47","pubTimestamp":1780987633,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，默沙东和吉利德科学表示，含有默沙东药物伊斯拉曲韦和吉利德药物莱那卡帕韦的复方药片的两项 3 期试验的初步结果达到了主要终点。此外，研究发现 islatravir/lenacapavir不劣于必妥维和标准口服抗逆转录病毒疗法。此外，两家公司宣布，根据数据监测委员会的建议，他们将终止吉利德的 Trodelvy 与默沙东的Keytruda一线治疗转移性非小细胞肺癌的 3 期 KEYNOTE-D46/EVOKE-03 研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1061106388.HKD","LU1093756325.SGD","LU1923622614.USD","LU1934455863.HKD","LU0265550359.USD","LU0114720955.EUR","BK4139","LU2112291526.USD","LU2125909247.SGD","BK4578","SG9999015978.USD","LU0320765646.SGD","LU1023059063.AUD","IE00B2B36J28.USD","SG9999015945.SGD","SGXZ57979304.SGD","IE00BKVL7J92.USD","LU0965508806.USD","BK4550","LU2433249047.HKD","LU1037948897.HKD","LU0432979614.USD","LU2491050154.USD","LU0265550946.USD","IE00B3T34201.USD","LU0980610538.SGD","LU0289739699.SGD","LU2491050071.SGD","LU0234570918.USD","BK4585","SG9999015358.SGD","SG9999015986.USD","LU1778281490.HKD","SG9999014575.USD","LU0130102774.USD","LU2361044949.HKD","BK4532","LU1093756168.USD","LU1116320901.HKD","SG9999014559.SGD","LU1571399168.USD","LU0965509283.SGD","LU0320765992.SGD","LU1934455194.USD","LU1585245621.USD","LU0868494617.USD","IE00BLSP4452.SGD","LU1035773651.USD","LU1069347547.HKD","LU2023250504.SGD","LU1066051225.USD","LU1674673428.USD","LU1066051498.USD","IE00B4R5TH58.HKD","LU1929549753.HKD","LU1989771016.USD","LU0320765489.SGD","LU1983299246.USD","LU1934455277.USD","LU0109394709.USD","IE00BJT1NW94.SGD","LU2324357040.USD","IE00BBT3K403.USD","LU1989772840.SGD","SG9999015341.SGD","SG9999002232.USD","LU0006306889.USD","GILD","LU1066053197.SGD","LU0985320562.USD","BK4566","IE00B19Z3581.USD","BK4007","IE0002270589.USD","LU0122379950.USD","SG9999014542.SGD","LU1201861249.SGD","LU0868494708.USD","IE0009355771.USD","LU1917777945.USD","IE00BSNM7G36.USD","LU1699723380.USD","LU0266013472.USD","LU1116320737.USD","LU2468319806.SGD","IE00BLSP4239.USD","LU0234572021.USD","SG9999001440.SGD","BK4588","LU0965509101.SGD","BK4568","LU2491049909.HKD","LU0965509010.AUD","LU1974910355.USD","MRK","LU2125154778.USD","SG9999002224.SGD","SG9999001176.SGD","LU0859254822.USD","SG9999014567.USD","LU1037948541.HKD","LU2357627491.SGD","IE00B19Z3B42.SGD","LU0203345920.USD","LU0203347892.USD","LU0106261372.USD","IE00B7SZLL34.SGD","IE00BN8TJ469.HKD","LU0882574055.USD","BK4583","LU1162221912.USD","IE00BJJMRZ35.SGD","LU0070302665.USD","BK4516","LU0889565916.HKD","LU2461242641.AUD","IE00BFTCPJ56.SGD","SG9999013999.USD","LU1430594728.SGD","LU2106854487.HKD","LU1941712264.USD","LU0211331839.USD","LU2087621335.USD","LU1066051811.HKD","LU2361044865.SGD","SG9999001176.USD","IE00B1BXHZ80.USD","BK4559","LU2023250843.SGD","LU1989772923.USD","LU0058720904.USD","BK4533","LU0238689110.USD","LU0648001328.SGD","LU0208291251.USD","LU1839511570.USD","LU1941712348.USD","LU2125154935.USD","LU0861579265.USD","LU1674673691.USD","LU2361045086.USD","LU0477156953.USD","LU0942090050.USD","IE000M9KFDE8.USD","LU0130517989.USD","LU0823416689.USD","LU2089984988.USD","SG9999015952.SGD","LU2125909593.SGD","IE0002141913.USD","LU1291159041.SGD","LU1057294990.SGD","IE00BZ1G4Q59.USD","BK4534","LU0098860793.USD","LU2360032135.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181239601","title":"吉利德科学：Islatravir/Lenacapavir HIV治疗方案在两项试验中均达到第48周主要疗效终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1181239601","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181239601?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:37","pubTimestamp":1780951065,"startTime":"0","endTime":"0","summary":"吉利德科学公司宣布，其基于islatravir与lenacapavir的HIV联合治疗方案，在两项关键临床试验中，均成功达到了预设的第48周主要疗效终点。这一积极结果标志着该创新疗法在抑制病毒载量方面展现出显著效果，为HIV感染者提供了潜在的全新长效治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU1057294990.SGD","LU0098860793.USD","BK4583","LU0058720904.USD","LU0211331839.USD","LU0965509101.SGD","LU0868494617.USD","LU1934455863.HKD","IE00BSNM7G36.USD","BK4139","LU1941712264.USD","LU1023059063.AUD","LU0861579265.USD","LU0980610538.SGD","IE00BBT3K403.USD","SG9999015945.SGD","LU0006306889.USD","LU1061106388.HKD","LU2361044949.HKD","LU0234570918.USD","LU0106261372.USD","LU0320765489.SGD","LU1571399168.USD","BK4585","LU0234572021.USD","LU0320765646.SGD","LU0859254822.USD","LU0965509283.SGD","SGXZ57979304.SGD","GILD","LU1929549753.HKD","LU2106854487.HKD","SG9999014542.SGD","LU1989772840.SGD","SG9999001176.SGD","LU2361044865.SGD","LU0265550359.USD","LU2491049909.HKD","BK4559","BK4516","LU1989771016.USD","LU1066053197.SGD","MRK","LU2360032135.SGD","LU0122379950.USD","LU0266013472.USD","LU0882574055.USD","LU1923622614.USD","IE00BZ1G4Q59.USD","BK4534","BK4007","IE00B7SZLL34.SGD","SG9999013999.USD","SG9999015986.USD","LU1037948541.HKD","LU0109394709.USD","LU0289739699.SGD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU1989772923.USD","SG9999002232.USD","LU1069347547.HKD","LU2357627491.SGD","LU2112291526.USD","LU0203347892.USD","IE0002270589.USD","LU1839511570.USD","LU2491050071.SGD","LU2125909247.SGD","LU2468319806.SGD","LU0965509010.AUD","LU1430594728.SGD","LU1066051811.HKD","LU0965508806.USD","LU0477156953.USD","BK4532","LU1093756168.USD","LU1585245621.USD","LU1162221912.USD","LU1035773651.USD","SG9999014575.USD","LU2125154935.USD","LU0070302665.USD","LU0823416689.USD","IE00B1BXHZ80.USD","SG9999002224.SGD","LU2023250504.SGD","IE00B19Z3581.USD","IE00BJJMRZ35.SGD","LU1037948897.HKD","BK4568","LU0320765992.SGD","LU0432979614.USD","LU0130517989.USD","LU2125909593.SGD","LU0942090050.USD","LU2023250843.SGD","IE0009355771.USD","IE00BLSP4452.SGD","IE00BFTCPJ56.SGD","LU0203345920.USD","LU1674673691.USD","LU0208291251.USD","SG9999015952.SGD","LU2125154778.USD","LU2433249047.HKD","SG9999015358.SGD","SG9999001176.USD","LU1917777945.USD","SG9999015978.USD","LU2461242641.AUD","LU2087621335.USD","IE00B4R5TH58.HKD","LU1983299246.USD","BK4588","SG9999014567.USD","LU1093756325.SGD","LU1778281490.HKD","LU1291159041.SGD","SG9999014559.SGD","BK4533","IE00B3T34201.USD","LU0985320562.USD","LU0238689110.USD","SG9999015341.SGD","LU0648001328.SGD","LU1116320901.HKD","IE00BKVL7J92.USD","LU2089984988.USD","IE00BJT1NW94.SGD","BK4578","LU1201861249.SGD","LU2324357040.USD","LU1974910355.USD","LU1116320737.USD","LU0130102774.USD","LU1941712348.USD","IE00B2B36J28.USD","LU1066051225.USD","LU0889565916.HKD","LU1934455277.USD","LU2491050154.USD","LU0868494708.USD","IE0002141913.USD","IE00BN8TJ469.HKD","LU0265550946.USD","BK4566","SG9999001440.SGD","LU2361045086.USD","LU1674673428.USD","LU1934455194.USD","LU1699723380.USD","LU1066051498.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":-0.037},{"period":"1month","weight":0.0332},{"period":"3month","weight":-0.0084},{"period":"6month","weight":-0.0487},{"period":"1year","weight":0.1423},{"period":"ytd","weight":0.0535}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.044916},{"month":2,"riseRate":0.428571,"avgChangeRate":0.008369},{"month":3,"riseRate":0.514286,"avgChangeRate":-0.011268},{"month":4,"riseRate":0.514286,"avgChangeRate":0.009883},{"month":5,"riseRate":0.571429,"avgChangeRate":0.020601},{"month":6,"riseRate":0.628571,"avgChangeRate":0.02322},{"month":7,"riseRate":0.571429,"avgChangeRate":0.016302},{"month":8,"riseRate":0.558824,"avgChangeRate":0.033158},{"month":9,"riseRate":0.558824,"avgChangeRate":0.031157},{"month":10,"riseRate":0.529412,"avgChangeRate":0.003173},{"month":11,"riseRate":0.647059,"avgChangeRate":0.039736},{"month":12,"riseRate":0.382353,"avgChangeRate":0.010114}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}